1. Home
  2. CXH vs ALXO Comparison

CXH vs ALXO Comparison

Compare CXH & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS Investment Grade Municipal Trust

CXH

MFS Investment Grade Municipal Trust

HOLD

Current Price

$7.94

Market Cap

65.6M

Sector

Finance

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.44

Market Cap

79.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CXH
ALXO
Founded
1989
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.6M
79.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CXH
ALXO
Price
$7.94
$1.44
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$3.30
AVG Volume (30 Days)
25.9K
279.7K
Earning Date
01-01-0001
11-07-2025
Dividend Yield
3.56%
N/A
EPS Growth
N/A
N/A
EPS
0.23
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$33.35
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.41
$0.40
52 Week High
$7.74
$2.27

Technical Indicators

Market Signals
Indicator
CXH
ALXO
Relative Strength Index (RSI) 44.86 50.89
Support Level $7.92 $1.29
Resistance Level $8.00 $1.56
Average True Range (ATR) 0.05 0.13
MACD -0.01 0.01
Stochastic Oscillator 16.67 51.09

Price Performance

Historical Comparison
CXH
ALXO

About CXH MFS Investment Grade Municipal Trust

Mfs Investment Grade Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowing for investment purposes, in tax-exempt bonds and tax-exempt notes.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: